Cooper M E, Allen T J, Macmillan P A, Clarke B E, Jerums G, Doyle A E
Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia.
Diabetologia. 1989 May;32(5):326-8. doi: 10.1007/BF00265552.
This study has evaluated the effects of the angiotensin converting enzyme inhibitor Enalapril on glomerular ultrastructure and albuminuria in normotensive and hypertensive diabetic rats. Streptozotocin-diabetes was induced in Wistar Kyoto and spontaneously hypertensive rats. Enalapril was administered in drinking water in diabetic normotensive, control hypertensive and diabetic hypertensive rats. Enalapril therapy prevented an increase in glomerular basement membrane thickness in diabetic normotensive, control hypertensive and diabetic hypertensive rats without any significant effect on fractional mesangial volume. Enalapril decreased albuminuria in diabetic normotensive, control hypertensive and diabetic hypertensive rats. Thus, enalapril retards the development of glomerular basement membrane thickening and albuminuria in the rat, in the presence or absence of hypertension.
本研究评估了血管紧张素转换酶抑制剂依那普利对正常血压和高血压糖尿病大鼠肾小球超微结构及蛋白尿的影响。在Wistar Kyoto大鼠和自发性高血压大鼠中诱导链脲佐菌素糖尿病。在糖尿病正常血压大鼠、对照高血压大鼠和糖尿病高血压大鼠的饮用水中给予依那普利。依那普利治疗可防止糖尿病正常血压大鼠、对照高血压大鼠和糖尿病高血压大鼠肾小球基底膜厚度增加,而对系膜分数容积无显著影响。依那普利可降低糖尿病正常血压大鼠、对照高血压大鼠和糖尿病高血压大鼠的蛋白尿。因此,无论有无高血压,依那普利均可延缓大鼠肾小球基底膜增厚和蛋白尿的发展。